OM Pharma (Switzerland)

Targeted lysosomal activation in bladder epithelium enhances clearance of intracellular uropathogenic Escherichia coli

Recurrent urinary tract infections (UTIs) are a major clinical burden, driven in part by the ability of uropathogenic Escherichia coli (UPEC) to establish intracellular niches within the bladder epithelium, where bacteria withstand antibiotics and host defenses. The oral bacteria...